Literature DB >> 15067712

Polyethylene glycol modification of filgrastim results in decreased renal clearance of the protein in rats.

Bing-Bing Yang1, Peggy K Lum, Michael M Hayashi, Lorin K Roskos.   

Abstract

This report provides the evidence that pegfilgrastim, which is produced by covalently binding a 20-kDa polyethylene glycol molecule to filgrastim, has decreased renal clearance compared with the native protein, filgrastim. After intravenous administration, the area under the plasma concentration versus time curve values for pegfilgrastim were significantly higher than those for filgrastim, indicating that the clearance was slower for pegfilgrastim. The concentration-time profiles of pegfilgrastim were similar between sham-operated and bilateral nephrectomized rats, suggesting that the kidney had an insignificant role in the elimination of pegfilgrastim. In contrast, bilateral nephrectomy resulted in decreased clearance of filgrastim by 60-75%. These data are consistent with the current knowledge that pegylation of proteins decreases the renal clearance of these conjugated proteins. Copyright 2004 Wiley-Liss, Inc. and the American Pharmacists Association J Pharm Sci 93:1367-1373, 2004

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15067712     DOI: 10.1002/jps.20024

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  26 in total

1.  Noninvasive detection of passively targeted poly(ethylene glycol) nanocarriers in tumors.

Authors:  Yashveer Singh; Dayuan Gao; Zichao Gu; Shike Li; Stanley Stein; Patrick J Sinko
Journal:  Mol Pharm       Date:  2011-11-22       Impact factor: 4.939

2.  A physiological model of granulopoiesis to predict clinical drug induced neutropenia from in vitro bone marrow studies: with application to a cell cycle inhibitor.

Authors:  Wenbo Chen; Britton Boras; Tae Sung; Yanke Yu; Jenny Zheng; Diane Wang; Wenyue Hu; Mary E Spilker; David Z D'Argenio
Journal:  J Pharmacokinet Pharmacodyn       Date:  2020-03-11       Impact factor: 2.745

Review 3.  Early engineering approaches to improve peptide developability and manufacturability.

Authors:  Jennifer L Furman; Mark Chiu; Michael J Hunter
Journal:  AAPS J       Date:  2014-10-23       Impact factor: 4.009

4.  Model-based approach to describe G-CSF effects in carboplatin-treated cancer patients.

Authors:  Mélanie L Pastor; Céline M Laffont; Laurence Gladieff; Antonin Schmitt; Etienne Chatelut; Didier Concordet
Journal:  Pharm Res       Date:  2013-06-26       Impact factor: 4.200

5.  Phase II, randomized, open-label study of pegfilgrastim-supported VDC/IE chemotherapy in pediatric sarcoma patients.

Authors:  Sheri L Spunt; Helen Irving; Jami Frost; Leonard Sender; Matthew Guo; Bing-Bing Yang; Lyndah Dreiling; Victor M Santana
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

6.  Model-based approach to early predict prolonged high grade neutropenia in carboplatin-treated patients and guide G-CSF prophylactic treatment.

Authors:  Mélanie L Pastor; Céline M Laffont; Laurence Gladieff; Etienne Chatelut; Didier Concordet
Journal:  Pharm Res       Date:  2014-09-04       Impact factor: 4.200

7.  Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative Maxy-G34 and pegfilgrastim in rats.

Authors:  M Scholz; C Engel; D Apt; S L Sankar; E Goldstein; M Loeffler
Journal:  Cell Prolif       Date:  2009-09-24       Impact factor: 6.831

Review 8.  G-CSF and GM-CSF in Neutropenia.

Authors:  Hrishikesh M Mehta; Michael Malandra; Seth J Corey
Journal:  J Immunol       Date:  2015-08-15       Impact factor: 5.422

9.  Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas.

Authors:  Elizabeth Fox; Brigitte C Widemann; Douglas S Hawkins; Nalini Jayaprakash; Ramzi Dagher; Alberta A Aikin; Donna Bernstein; Lauren Long; Crystal Mackall; Lee Helman; Seth M Steinberg; Frank M Balis
Journal:  Clin Cancer Res       Date:  2009-11-17       Impact factor: 12.531

10.  Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model.

Authors:  Markus Scholz; Manuela Ackermann; Frank Emmrich; Markus Loeffler; Manja Kamprad
Journal:  Biologics       Date:  2009-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.